C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
P. Harrington,Richard Dillon,Deepti Radia,Philippe Rousselot,Donal P. McLornan,Mark L H Ong,Anna Green,Alessandro Verde,Farzana S Hussain,Kavita Raj,Shahram Kordasti,Claire N. Harrison,Hugues de Lavallade +12 more
TL;DR: Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling as mentioned in this paper , and patients on Dasatinib showed inhibition of both Tcell receptor (TCR) and STAT5 signaling pathways, and reduced expression of T-effector pro-inflammatory cytokines.
Journal ArticleDOI
Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.
Helen O. Ajufo,Jan Philipp Bewersdorf,Claire N. Harrison,Francesca Palandri,John Mascarenhas,Jeanne Palmer,Aaron T. Gerds,Jean-Jacques Kiladjian,Andriy Derkach,Raajit K. Rampal,S. Buckley,Karisse Roman-Torres +11 more
TL;DR: In this paper , the authors presented a landmark analysis of the relationship between SVR and OS on PERSIST-2 patients who were alive and on study at the start of the 12-week SVR window.
Journal ArticleDOI
Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden
Jeanne Palmer,Aaron T. Gerds,Claire N. Harrison,Jean-Jacques Kiladjian,S. Buckley,Karisse Roman-Torres,John Mascarenhas,Ruben A. Mesa +7 more
TL;DR: In this article , the authors found that patients with isolated thrombocytopenia have higher symptom burden than those with isolated anemia, and that anemia may not be the sole driver of symptom burden.
Journal ArticleDOI
Increasing therapeutic efficacy in MPN.
TL;DR: An elegant series of experiments show that genetic deletion in the hematopoietic system of Janus kinase 2 (JAK2) abrogates initiation of myeloproliferative disease and substantial disease regression if deleted once disease is initiated.